Sanoculis Receives CE Mark for Innovative MINT® Treatment for Glaucoma

Sanoculis Achieves CE Mark for MINT® Technology in Glaucoma Treatment

Sanoculis Ltd., a prominent name in ophthalmic medical device technology, announced a significant milestone with the receipt of the CE Mark for its groundbreaking MINT® (Minimally Invasive Nasal Trabeculostomy) product. This innovative, stent-free technology is designed specifically for adult patients requiring surgical intervention for glaucoma, a condition affecting millions globally.

Understanding Glaucoma and Its Impact

Glaucoma is a chronic eye disease that can lead to irreversible blindness if not detected and treated timely. By 2040, the global population diagnosed with this condition is expected to surge from 76 million to approximately 112 million. Patients often experience elevated intraocular pressure (IOP) which results in damage to the optic nerve and can lead to significant vision loss over time. Early diagnosis and treatment are vital to preserving eyesight, making innovative treatment solutions essential in the fight against this ailment.

The MINT® Breakthrough

The MINT® technology utilizes a unique semi-automatic trepanation technique, featuring a tip diameter of just 0.14 mm, to create precise openings in the trabecular meshwork. This stent-free approach aims to elevate the standard of care by offering a less invasive and more effective option for glaucoma patients. Nir Israeli, Co-founder and CEO of Sanoculis, emphasized that MINT® represents a transformative advancement in minimally invasive glaucoma surgery (MIGS). The clinical data gathered from a two-year prospective study demonstrates that MINT® not only safely lowers IOP but also reduces reliance on glaucoma medications.

Future Market Introduction Plans

Sanoculis is gearing up for a selective market launch of the MINT® technology later this year, intending to make this innovative solution accessible to patients in need. The company’s commitment to enhancing treatment standards showcases its dedication to improving outcomes for glaucoma patients through revolutionary stent-free solutions.

As the prevalence of glaucoma continues to rise, the MINT® innovation from Sanoculis could represent a crucial shift in how this serious condition is managed. By prioritizing earlier intervention through innovative techniques, there is potential for improved patient experiences and outcomes.

Conclusion

The advancement marked by the CE Mark for MINT® reflects Sanoculis' pursuit of quality and innovation in ophthalmic technologies. In a landscape where glaucoma remains a leading cause of blindness, MINT® stands out as a promising option, and its selective introduction will be closely watched by both practitioners and patients alike. As the company prepares to roll out this cutting-edge solution, the focus remains on improving care for individuals battling glaucoma, ultimately enhancing their quality of life and safeguarding their vision.

For further inquiries regarding MINT® and its applications, interested parties can contact:

Elad Shalev
VP of Global Marketing and Sales
Email: [email protected]
Phone: +972 509 827 282